Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
10.16 (1y: +209%)
Market Cap 270.43 M P/E(ttm)
Enterprise Value 254.99 M P/B 19.61
TEAR- NAS (USA)
TearLab Corpoartion
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$10.16
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt No Debt
TEAR's Cash to Debt is ranked higher than
81% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.56 vs. TEAR: No Debt )
TEAR' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: No Debt
Equity to Asset 0.414
TEAR's Equity to Asset is ranked lower than
53% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. TEAR: 0.414 )
TEAR' s 10-Year Equity to Asset Range
Min: -1.66   Max: 0.41
Current: 0.41
-1.66
0.41
Interest Coverage No Debt
TEAR's Interest Coverage is ranked higher than
98% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. TEAR: No Debt )
TEAR' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: -8.15
M-Score: -4.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -303.80
TEAR's Operating margin (%) is ranked lower than
82% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. TEAR: -303.80 )
TEAR' s 10-Year Operating margin (%) Range
Min: -42534   Max: 45657.6
Current: -303.8
-42534
45657.6
Net-margin (%) -487.7
TEAR's Net-margin (%) is ranked lower than
82% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. TEAR: -487.7 )
TEAR' s 10-Year Net-margin (%) Range
Min: -74064.1   Max: -392.9
Current: -487.7
-74064.1
-392.9
ROE (%) -130.1
TEAR's ROE (%) is ranked lower than
78% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. TEAR: -130.1 )
TEAR' s 10-Year ROE (%) Range
Min: -1155.1   Max: -7.6
Current: -130.1
-1155.1
-7.6
ROA (%) -80
TEAR's ROA (%) is ranked lower than
83% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. TEAR: -80 )
TEAR' s 10-Year ROA (%) Range
Min: -681.5   Max: -7.2
Current: -80
-681.5
-7.2
Revenue Growth (%) 25
TEAR's Revenue Growth (%) is ranked higher than
64% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. TEAR: 25 )
TEAR' s 10-Year Revenue Growth (%) Range
Min: -66.8   Max: 31.6
Current: 25
-66.8
31.6
EBITDA Growth (%) 6.3
TEAR's EBITDA Growth (%) is ranked lower than
52% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.85 vs. TEAR: 6.3 )
TEAR' s 10-Year EBITDA Growth (%) Range
Min: -68.4   Max: 66.6
Current: 6.3
-68.4
66.6
EPS Growth (%) 14.6
TEAR's EPS Growth (%) is ranked higher than
52% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.90 vs. TEAR: 14.6 )
TEAR' s 10-Year EPS Growth (%) Range
Min: -68.7   Max: 49.9
Current: 14.6
-68.7
49.9
ยป TEAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TEAR



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 19.61
TEAR's P/B is ranked lower than
78% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. TEAR: 19.61 )
TEAR' s 10-Year P/B Range
Min: 0.18   Max: 39.73
Current: 19.61
0.18
39.73
P/S 67.73
TEAR's P/S is ranked lower than
92% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. TEAR: 67.73 )
TEAR' s 10-Year P/S Range
Min: 5.5   Max: 416.67
Current: 67.73
5.5
416.67
EV-to-EBIT -21.19
TEAR's EV-to-EBIT is ranked lower than
78% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. TEAR: -21.19 )
TEAR' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 0.4
Current: -21.19
0.1
0.4

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 47
TEAR's Price/Net Cash is ranked higher than
84% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.65 vs. TEAR: 47 )
TEAR' s 10-Year Price/Net Cash Range
Min: 1.6   Max: 11.7
Current: 47
1.6
11.7
Price/Net Current Asset Value 149.8
TEAR's Price/Net Current Asset Value is ranked higher than
90% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.40 vs. TEAR: 149.8 )
TEAR' s 10-Year Price/Net Current Asset Value Range
Min: 0.5   Max: 200
Current: 149.8
0.5
200
Price/Tangible Book 29.3
TEAR's Price/Tangible Book is ranked higher than
89% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. TEAR: 29.3 )
TEAR' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 54.8
Current: 29.3
1.5
54.8
Price/Median PS Value 2.8
TEAR's Price/Median PS Value is ranked higher than
79% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. TEAR: 2.8 )
TEAR' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 8.4
Current: 2.8
0.2
8.4
Earnings Yield (Greenblatt) 1729.30
TEAR's Earnings Yield (Greenblatt) is ranked higher than
99% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. TEAR: 1729.30 )
TEAR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 256.6   Max: 2535
Current: 1729.3
256.6
2535
Forward Rate of Return (Yacktman) -16.29
TEAR's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. TEAR: -16.29 )
TEAR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 3.3
Current: -16.29
2.5
3.3

Business Description

TearLab Corp. was incorporated as OccuLogix, Inc. in Delaware in 2002. It is an in-vitro diagnostic company based in San Diego, California. The Company is commercializing a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. TearLab Research, Inc. its wholly-owned subsidiary, develops technologies to enable eye care practitioners to test a wide range of biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is now the focus of its business. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and highly specific biomarker that has been shown to assist in the diagnosis and disease management of DED. There are estimated to be between 20 million and 40 million DED patients in the United States, and less than 5% of those patients are currently diagnosed and treated. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using a highly efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. Government authorities in the United States and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of its product, which is a medical device.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ
Traded in other countries:TLB.Canada
ยป More Articles for TEAR

Headlines

Articles On GuruFocus.com

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial